FDA approves AstraZeneca’s Imjudo, Imfinzi combo for unresectable HCC
The approval by the US regulator was based on the findings of the HIMALAYA phase 3 trial which…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
25 Oct 22
The approval by the US regulator was based on the findings of the HIMALAYA phase 3 trial which…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 Oct 22
DJS Antibodies is engaged in the development and commercialisation of antibody medicines that target difficult-to-drug disease-causing proteins, and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 Oct 22
Roche will pay an upfront amount of $25m to HOOKIPA Pharma and potential payments of up to $930m…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
20 Oct 22
Under the terms of the deal, Jazz will obtain exclusive rights to develop and commercialise zanidatamab worldwide, excluding…
20 Oct 22
The FDA Emergency Use Authorisation decision was based on the findings of the phase 3 Prevent-19 clinical trial…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
19 Oct 22
Under the long-term license agreement with WBCP, a series of innovative new flavors unites the epic excitement of…
19 Oct 22
The global market for CBD is expected to reach $4.09 billion by 2030 from $1.80 billion in 2021, registering impressive expansion at…
19 Oct 22
The proposed acquisition, valued at around $487m plus a contingent value right for up to $610m, is expected…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
19 Oct 22
The South Korean company said that the acquisition will extend the commercial footprint of its life sciences division…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
18 Oct 22
MacroGenics will receive an upfront payment of $60m and is eligible to receive up to $1.7bn in potential…